1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
67060B395B91A473C0025871200238B06
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-field-medical-excellence-optimizing-performance?opendocument
18
19opendocument
203.239.58.199
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Medical Science Liaison

Field Medical Excellence: Optimizing Performance

ID: 5685


Features:

5 Info Graphics

15 Data Graphics

180+ Metrics

6 Narratives


Pages/Slides: 27


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Field Medical Excellence: Optimizing Performance”

STUDY OVERVIEW

As the effectiveness of traditional physician access channels fluctuates in the COVID era, Medical Affairs leaders must refine the activities and engagement tactics of their field medical teams to maximize their interactions with thought leaders. Consequently, there is a need to establish new performance benchmarks to measure the effectiveness of field medical specialists.

Best Practices, LLC conducted this benchmarking research to identify competitive field medical team performance metrics in key global markets.

In particular, this study provides a wide range of field-based benchmarks across productivity measures, efficiency indicators, frequency of thought leader interactions by tier, effective communication channels, and new approaches to measure field impact.

KEY TOPICS

  • Thought Leader Targeting and Engagement Levels
  • Assessing Field Activity Impact and Efficiency
  • New and High-Impact Field Activities

KEY METRICS

  • On average, how many thought leaders do each of your MSLs support?
  • For a typical MSL, approximately what percentage of all the thought leaders they support can be classified according to the listed tiers?
  • How frequently do your MSLs interact with each kind of thought leader on average?
  • What is the monthly goal vs. actual number of interactions by MSLs?
  • What is your MSL’s average time spent in each face-to-face thought leader interaction?
  • What percentage of your MSLs’ thought leader interactions are proactive and reactive?
  • For a typical MSL, approximately what percentage of interactions with a given thought leader take place on each of the listed communication channels?
  • How much time do your MSLs spend on average on the listed external activities each week – and what is the ideal amount of spent on each activity per week?
  • How effective are each of the listed performance indicators in assessing the performance of your MSLs?
  • What new Key Performance Indicators (KPIs) or metrics has your organization adopted to assess field team performance in the current environment?
  • In your experience, how effective are the listed types of previous work experience in enabling your MSLs and other team members to be effective in the field?
  • Within your region, how are medical information inquiries handled?

SAMPLE KEY FINDINGS

  • Half of interactions are virtual: Roughly half of all MSL interactions with thought leaders have moved to virtual platforms like Zoom, and the use of email and phone has also grown to supplement lost F2F time. MSLs now average 13 hours of total direct weekly KOL interaction time, regardless of channel.

METHODOLOGY

Best Practices, LLC engaged 100 Field Medical and Medical Affairs leaders from 62 biopharmaceutical companies through a benchmarking survey. More than half of research participants serve as Field Medical or Medical Affairs directors, while over 15% of participants serve at the executive level.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Consulting; Medical Device; Manufacturing; Consumer Products; Diagnostic; Health Care; Communications; Clinical Research; Laboratories


Companies Profiled:
Adamas Pharmaceuticals; Alkermes; Alnylam Pharmaceuticals; Amgen; Apellis Pharmaceuticals; Arcutis Biotherapeutics; ASC Therapeutics; Ashfield Healthcare; Astellas; AstraZeneca; Aurinia Pharmaceuticals; Baxter Healthcare; Bayer; BeiGene; BioMarin; Boehringer Ingelheim; Chiesi; Cipla; Clovis Oncology; Curis; Daiichi Sankyo; Dova Pharmaceuticals; Dr Reddy's Laboratories; Eisai; ERYTECH; Eurofarma; Foundation Medicine; GE Healthcare; Gilead Sciences; GlaxoSmithKline ; Greenwich Biosciences; Grifols; Grünenthal; Kartos Therapeutics; Kiniksa Pharmaceuticals; Kyowa Kirin; Legend Biotech; LEO Pharma; Merck; Mesoblast; Miravo Healthcare; NexGen Healthcare Communications; Novartis; Novo Nordisk; OM Pharma; Paratek Pharmaceuticals; Pfizer; Pharmacosmos Therapeutics Inc.; Radius Health; Inc.; Reata Pharmaceuticals; Sanofi; Sanofi Genzyme; Servier; Sunovion; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; Theravance; Travere Therapeutics; Urovant Sciences; Vertex Pharmaceuticals; Vifor Pharma; Zogenix

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.